Filtered By:
Condition: Diabetes
Cancer: Cancer
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 147 results found since Jan 2013.
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Nanocarriers and Diabetes: New Vistas and the way ahead
Curr Pharm Biotechnol. 2022 Dec 27. doi: 10.2174/1389201024666221227140728. Online ahead of print.ABSTRACTWorld Health Organization has reported an estimated 1.5 million deaths directly due to diabetes in 2019. Center for Disease Control and Prevention, in its National Diabetes Statistics Report, 2020, says that 1 in 10 United States residents has diabetes. This rapid progression of diabetes is noteworthy despite significant advances in the field of antidiabetic medicine. The critical challenges in treatment are dyslipidemia, hyperinsulinemia, and hyperglycemia. The latest research has also linked diabetes to carcinogenesi...
Source: Current Pharmaceutical Biotechnology - December 29, 2022 Category: Biotechnology Authors: Pankaj V Dixit Dinesh K Mishra Sanjay Sharma Rupesh K Gautam Source Type: research
Comment on: Insurance-mandated weight management program completion before bariatric surgery provides no long-term clinical benefit
By 2030, 1 in 2 American adults is projected to have obesity and 1 in 4 clinically severe obesity. Obesity represents a serious public health issue because it is a major risk factor for many major, noncommunicable diseases, such as type 2 diabetes, coronary heart disease, stroke, chronic obstructive pulmonary disease, and cancer, and independently predicts overall mortality. The burden of obesity on medical spending is also significant, with $1861 in excess annual medical costs per adult with obesity and $3097 per adult with severe obesity —accounting for $173 billion annually in the United States [1].
Source: Surgery for Obesity and Related Diseases - November 15, 2022 Category: Surgery Authors: Hamlet Gasoyan, David B. Sarwer, Michael B. Rothberg Tags: Editorial comment Source Type: research
Precertification criteria for bariatric surgery should be based on evidence
By 2030, one in two American adults is projected to have obesity and one in four clinically severe obesity. Obesity represents a serious public health issue because it is a major risk factor for many major, non-communicable diseases, such as type 2 diabetes, coronary heart disease, stroke, chronic obstructive pulmonary disease, and cancer, and independently predicts overall mortality. The burden of obesity on medical spending is also significant, with $1,861 excess annual medical costs per adult with obesity and $3,097 per adult with severe obesity – accounting for $173 billion annually in the United States.
Source: Surgery for Obesity and Related Diseases - November 15, 2022 Category: Surgery Authors: Hamlet Gasoyan, David B. Sarwer, Michael B. Rothberg Source Type: research
The Prevalence of Multimorbidity among Foreign-born Adults in the United States
CONCLUSIONS: The prevalence of multimorbidity among immigrants was lower than the prevalence in the overall US population of the same age, consistent with studies showing an immigrant health advantage.PMID:35909642 | PMC:PMC9311306 | DOI:10.18865/ed.32.3.213
Source: Ethnicity and Disease - August 1, 2022 Category: International Medicine & Public Health Authors: Rebecca E Jones Lubaba Tasnim Solveig A Cunningham Source Type: research
